Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer

Impact: Health impacts

Narrative

The study investigated safety and overall survival in radium-223 treated patients in an early access programme done after the ALSYMPCA study and before regulatory approval of radium-223.

Category of impact

  • Health impacts
Date
2016

Related information